Fig. 8

LncRNA-p21/EZH2/STAT3 signal is activated in PDX mice model after Enz treatment and human NEPC samples. a The PCa PDX samples were subcutaneously implanted into SCID mice and 5 mice/group received different i.p. treatments (1. DMSO; 2. Enz; 3. Dznep; 4. Dznep + Enz) every other day, and tumor sizes were measured after different treatments. After 10 treatments, the mice were kept for another 2 days and then were sacrificed.The PDX tumors were collected, and the relative tumor growth rates of different treatments were compared. b The IHC staining to identify the level of NE markers indicated in different groups (Scale bar = 20 μm). c Three tumor samples were randomly picked up from each group, the tissues were lysed and then STAT3 methylation (methyl-k) was detected by WB. d The lncRNA-p21 levels in control group and Enz-treated group were detected by qPCR. e The correlation of lncRNA-p21 expression and p-EZH2 level in human PCa samples (n = 80). f Representative images of the immunohistochemistry staining of SYP, ChgA, p-EZH2 and p-STAT3 in human CRPC and SCC samples. (Scale bar = 20 μm). g The quantification of p-EZH2 (upper) and p-STAT3 (lower) levels in human CRPC and PCa-SCC samples. For a, e, g, the data are presented as mean ± SD, **p < 0.005, by t test for two groups or ANOVA for more than two groups